A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours

Peer Review reports

Original Submission
29 Jul 2020	Submitted	Original manuscript
17 Sep 2020	Reviewed	Reviewer Report - Joseph Abi Jaoude
22 Sep 2020	Reviewed	Reviewer Report
20 Oct 2020	Author responded	Author comments - Yvonne LE Ang
Resubmission - Version 2
20 Oct 2020	Submitted	Manuscript version 2
21 Oct 2020	Reviewed	Reviewer Report - Joseph Abi Jaoude
26 Oct 2020	Reviewed	Reviewer Report
2 Nov 2020	Author responded	Author comments - Yvonne LE Ang
Resubmission - Version 3
2 Nov 2020	Submitted	Manuscript version 3
Publishing
4 Nov 2020	Editorially accepted
17 Nov 2020	Article published	10.1186/s12885-020-07616-4

Back to article page